https://www.webmd.com/breast-cancer/breast-cancer-brca-gene-test#1
GTG was performing BRACA under the licence from Myriad in Australia.
Now no licence necessary. Brevagen is just complementary.
The new Board was proposing to Roll Out Brevagen in Australia I reason they would do together with BRACA which is less volume but much higher price.
In US Myriad has Brand Name but in Australia GTG can roll out with no opposition then move on to the World.
Myriad started as a small company and GENE can do it too under a right management and with advantage of Blockchain.
Just my opinion.
- Forums
- ASX - By Stock
- GTG
- Breast Cancer (BRCA) Gene
GTG
genetic technologies limited
Add to My Watchlist
0.00%
!
3.9¢

Breast Cancer (BRCA) Gene
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $52.08M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
GTG (ASX) Chart |
Day chart unavailable